Clinical Trial Update: A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer

Drugs mentioned

• TRI-611 (TRI-611)

Snippet

Sponsor: TRIANA Biomedicines, Inc. | Conditions: ALK-positive NSCLC, ALK-Positive Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING